Speaking to The Financial Express, British Biologicals managing director Dr VS Reddy said, ‘‘The R&D wing is also working on a protein supplement for cancer patients, which would help in weight maintenance due to radiation and chemotherapy.’’
The product would be a combination of six flavours in one pack. British Biologicals would be bringing out 18 disease-based neutraceutical products in the next two to three years, Dr Reddy said. The new product portfolio would also include products for ageing and cholestrol control, Dr Reddy added.
The company has tied up with a Finland-based firm to market their cholesterol control product in Third-World countries. It would be sold under the label of the Finland company, Dr Reddy said. The company, which is already exporting to nine countries across the world, would enter the UK markets this year and entry to the US markets is slated for next year, Dr Reddy said. British Biologicals is also looking at tie-ups in the US for technical knowhow in new areas. The company, which has posted an export turnover of Rs 7 crore in 2000-2001, is expecting to record Rs 20 crore in the next two years with the introduction of new products.